Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,647 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Thummalapalli R, Bernstein E, Herzberg B, Li BT, Iqbal A, Preeshagul I, Santini FC, Eng J, Ladanyi M, Yang SR, Shen R, Lito P, Riely GJ, Sabari JK, Arbour KC. Thummalapalli R, et al. Among authors: shen r. JCO Precis Oncol. 2023 Jun;7:e2300030. doi: 10.1200/PO.23.00030. JCO Precis Oncol. 2023. PMID: 37384866 Free PMC article.
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas.
Girard N, Shen R, Guo T, Zakowski MF, Heguy A, Riely GJ, Huang J, Lau C, Lash AE, Ladanyi M, Viale A, Antonescu CR, Travis WD, Rusch VW, Kris MG, Pao W. Girard N, et al. Among authors: shen r. Clin Cancer Res. 2009 Nov 15;15(22):6790-9. doi: 10.1158/1078-0432.CCR-09-0644. Epub 2009 Oct 27. Clin Cancer Res. 2009. PMID: 19861435 Free PMC article.
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
Rizvi NA, Rusch V, Pao W, Chaft JE, Ladanyi M, Miller VA, Krug LM, Azzoli CG, Bains M, Downey R, Flores R, Park B, Singh B, Zakowski M, Heelan RT, Shen R, Kris MG. Rizvi NA, et al. Among authors: shen r. Clin Cancer Res. 2011 May 15;17(10):3500-6. doi: 10.1158/1078-0432.CCR-10-2102. Epub 2011 May 10. Clin Cancer Res. 2011. PMID: 21558399 Free PMC article. Clinical Trial.
Prognostic immune markers in non-small cell lung cancer.
Suzuki K, Kachala SS, Kadota K, Shen R, Mo Q, Beer DG, Rusch VW, Travis WD, Adusumilli PS. Suzuki K, et al. Among authors: shen r. Clin Cancer Res. 2011 Aug 15;17(16):5247-56. doi: 10.1158/1078-0432.CCR-10-2805. Epub 2011 Jun 9. Clin Cancer Res. 2011. PMID: 21659461 Review.
Integrative subtype discovery in glioblastoma using iCluster.
Shen R, Mo Q, Schultz N, Seshan VE, Olshen AB, Huse J, Ladanyi M, Sander C. Shen R, et al. PLoS One. 2012;7(4):e35236. doi: 10.1371/journal.pone.0035236. Epub 2012 Apr 23. PLoS One. 2012. PMID: 22539962 Free PMC article.
2,647 results